AbbVie
1 North Waukegan Road
North Chicago
Illinois
60064
United States
Tel: 1-800-255-5162
Website: http://www.abbvie.com/
Email: customerservice@abbvie.com
About AbbVie
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
Stock Symbol: ABBV
Stock Exchange: NYSE
People. Passion. Possibilities. Those three simple words mean everything at AbbVie, where patients always come first. So do cutting-edge science and innovation, which fuel our expanding pipeline as we take on the world's toughest health challenges in oncology, immunology, liver disease, women's health and beyond. Together, we strive to make a difference for patients around the world. For more visit: www.abbvie.com.
867 articles with AbbVie
-
AbbVie Announces Positive Results from CLL14, a Phase 3 Trial Evaluating a Venetoclax Combination as First-Line Therapy with a Fixed Duration of Treatment in Patients with Chronic Lymphocytic Leukemia
10/31/2018
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive results from CLL14, a Phase 3, randomized clinical trial evaluating venetoclax plus obinutuzumab versus obinutuzumab plus chlorambucil,
-
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
-
What is AbbVie thinking? That’s the question of many investors, analysts and industry watchers as the Chicago-based AbbVie decided to buy up researcher partner Galapagos' cystic fibrosis portfolio instead of walking away.
-
Galapagos and AbbVie restructure CF collaboration
10/24/2018
Galapagos NV announce a restructuring of their cystic fibrosis (CF) alliance; AbbVie takes over all programs in CF and continues the development of a triple combination therapy for CF.
-
Eli Lilly Updates Spondyloarthritis Trial Data and Long-Term Rheumatoid Arthritis Studies
10/24/2018
Eli Lilly and Company presented positive data from two Phase III clinical trials at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Chicago yesterday. -
AbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program
10/24/2018
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that it will assume full development and commercial responsibility for its collaboration with Galapagos (Euronext: GLPG) to discover and develop new therapies to treat cystic fibrosis (CF).
-
AbbVie's Upadacitinib Shows Significant Improvements in Physical Function, Pain and Quality of Life as a Monotherapy in Patients with Rheumatoid Arthritis in Phase 3 Patient-Reported Outcomes Data
10/23/2018
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new patient-reported outcomes data from the ongoing Phase 3 SELECT-MONOTHERAPY trial evaluating upadacitinib (
-
Positive Phase 2b Data for AbbVie's Upadacitinib Show Significant Induction of Clinical Remission and Response in Patients with Ulcerative Colitis
10/22/2018
In U-ACHIEVE, upadacitinib (15/30/45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints, including endoscopic improvement, clinical remission (per Full Mayo Score) and clinical response, in patients with moderately to severely active ulcerative colitis[1]
-
BioSpace Movers and Shakers - Oct. 22
10/22/2018
Execs at Novo Nordisk, AbbVie, and more made moves this week. Here's a roundup of those changes. -
AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases
10/18/2018
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, andMorphic Therapeutic, a biotechnology company developing oral integrin therapies, announced today that the companies have entered into a research and development collaboration designed to advance a number of Morphic's oral integrin therapeutics for fibrosis-related indications.
-
AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Fresenius Kabi
10/18/2018
Agreements Provide Non-Exclusive License to Fresenius Kabi for HUMIRA-Related Intellectual Property in the U.S. Effective September 30, 2023, and in Other Markets on Different Dates
-
AbbVie Invests $100 Million in Morphic Therapeutics to Develop Integrin Inhibitors for Fibrotic D...
10/18/2018
Weeks after Waltham, Mass.-based Morphic Therapeutic secured $80 million in Series B financing that was supported in part by AbbVie Ventures, the company struck a deal with the pharma giant to collaborate on the development of therapies for fibrosis-related indications. -
Recently, 23andMe partnered with GlaxoSmithKline, causing the Forbes Technology Council to cite eight ways these types of partnerships will affect disease treatments. These types of partnerships aren’t exactly new.
-
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
10/17/2018
Abbvie announced that FDA has accepted its supplemental New Drug Application
-
AbbVie’s Humira is the world’s best-selling drug that generated more than $18 billion for the Illinois-based company last year. This week though, the company will begin to see challenges to Humira in Europe from biosimilars developed by Amgen and Novartis, as well as others.
-
AbbVie Reinforces Leadership in Gastroenterology with New Data Showcasing Research Advancements Across Robust Portfolio at United European Gastroenterology (UEG) Week 2018
10/16/2018
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present new data across investigational medicines and HUMIRA® (adalimumab) at United European Gastroenterology (UEG) Week 2018 from October 20-24 in Vienna.
-
AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Sandoz
10/11/2018
AbbVie announced today a global resolution of all intellectual property-related litigation with Sandoz over its proposed biosimilar adalimumab product.
-
Nobel Prizes Underscore Benefits of Research, but Also Highlight ‘Worst Instincts’ of Industry: R...
10/9/2018
In a report, Bloomberg said that pharma’s “efforts to maximize (financial) gains” has led to the coloring of R&D decisions and creating barriers to the entry of competing medications that can add costs to the health care system. -
AbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting
10/8/2018
- Oral presentations include three of the five pivotal studies from AbbVie's SELECT Phase 3 program to support regulatory submission for investigational upadacitinib in patients with moderate to severe rheumatoid arthritis
-
Frances Arnold 5th Woman to Win Nobel Prize in Chemistry, Joining Madame Curie and Her Daughter
10/3/2018
The 2018 Nobel Prize in chemistry was awarded to Frances H. Arnold, George P. Smith and Gregory P. Winter for research in utilizing evolutionary principles to create proteins.